The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Treatment of Primary Sjögren Syndrome: A Systematic Review
Abstract
CONTEXT: A variety of topical and systemic drugs are available to treat primary Sjögren syndrome, although no evidence-based therapeutic guidelines are currently available. OBJECTIVE: To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials. DATA SOURCES: We searched MEDLINE and EMBASE for articles on drug therapy for primary Sjögren syndrome published between January 1, 1986, and April 30, 2010. STUDY SELECTION: Controlled trials of topical and systemic drugs including adult patients with primary Sjögren syndrome were selected as the primary information source. RESULTS: The search strategy yielded 37 trials. A placebo-controlled trial found significant improvement in the Schirmer and corneal staining scores, blurred vision, and artificial tear use in patients treated with topical ocular 0.05% cyclosporine. Three placebo-controlled trials found that pilocarpine was associated with improvements in dry mouth (61%-70% vs 24%-31% in the placebo group) and dry eye (42%-53% vs 26%). Two placebo-controlled trials found that cevimeline was associated with improvement in dry mouth (66%-76% vs 35%-37% in the placebo group) and dry eye (39%-72% vs 24%-30%). Small trials (<20 patients) found no significant improvement in sicca outcomes for oral prednisone or hydroxychloroquine and limited benefits for immunosuppressive agents (azathioprine and cyclosporine). A large trial found limited benefits for oral interferon alfa-2a. Two placebo-controlled trials of infliximab and etanercept did not achieve the primary outcome (a composite visual analog scale measuring joint pain, fatigue, and dryness); neither did 2 small trials (<30 patients) testing rituximab, although significant results were observed in some secondary outcomes and improvement compared with baseline. CONCLUSIONS: In primary Sjögren syndrome, evidence from controlled trials suggests benefits for pilocarpine and cevimeline for sicca features and topical cyclosporine for moderate or severe dry eye. Anti-tumor necrosis factor agents have not shown clinical efficacy, and larger controlled trials are needed to establish the efficacy of rituximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E., Gottenberg, J.-E., Bootsma, H., Mariette, X., & Vitali, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 965
Self-citationSall, K., Stevenson, O. D., Mundorf, T. K., & Reis, B. L. (2000) · Ophthalmology · doi:10.1016/s0161-6420(99)00176-1 · Cited by 916
Clinical Manifestations and Early Diagnosis of Sjögren Syndrome
Kassan, S. S., & Moutsopoulos, H. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1275 · Cited by 698
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488
Vivino, F. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.2.174 · Cited by 448
Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 437
Dass, S., Bowman, S. J., Vital, E. M., Ikeda, K., Pease, C. T., Hamburger, J., Richards, A., Rauz, S., & Emery, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083865 · Cited by 431
Stevenson, D., Tauber, J., & Reis, B. L. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00035-x · Cited by 425
Cited by
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Mariette, X., & Criswell, L. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1702514 · Cited by 947
Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Self-citationEULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Self-citation
Metadata
- Authors
- Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A., & Bosch, X.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-07-28
- Volume
- 304
- Issue
- 4
- Pages
- 452
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2078958726
- Cited by
- 381
- References
- 47
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Primary Sjögren Syndrome: A Systematic Review. https://app.cochat.ai/papers/10.1001/jama.2010.1014
- The paper
- Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A., & Bosch, X. (2010). Treatment of Primary Sjögren Syndrome: A Systematic Review. JAMA. https://doi.org/10.1001/jama.2010.1014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.